1. BCLC Outperforms HKLC Staging of Hepatocellular Carcinoma in Multiethnic Asians – Real-World Perspective
ESPS Manuscript NO: 32584

2. Figure 1a. Barcelona Clinic Liver Cancer (BCLC) staging system2

3. Figure 1b. Hong Kong Liver Cancer (HKLC) staging system5

4. Figure 2a. Kaplan-Meier survival curve according to BCLC staging system
Cumulative Survival 5 10 15 20 25
Survival Time (Years)

5. Figure 2b. Kaplan-Meier survival curve according to HKLC staging system
Cumulative Survival 5 10 15 20 25 30
Survival Time (Years)

6. Figure 3. Patients receiving curative treatment after assignment to curative treatment groups by BCLC and HKLC staging systems
Percentage
BCLC Curative
Stages 0 and A
HKLC Curative
Stages I, II and Va
BCLC Stage 0
BCLC Stage A
HKLC Stage I
HKLC Stage II
HKLC Stage Va
*Figures in percentage

7. Age (in years) / Percentage
Figure 4. Comparison of characteristics of patients assigned by HKLC staging system to curative treatment who did and did not receive recommended treatment
Age (in years) / Percentage

8. Figure 5. Median survival of patients assigned to curative treatment by BCLC and HKLC staging systems
Cumulative Survival 5 10 15 20 25 30
Survival Time (Years)

9. Figure 6. Median survival of patients who received the assigned curative treatment according to the BCLC and HKLC staging systems
Cumulative Survival 5 10 15 20 25 30
Survival Time (Years)

10. Table 1. Baseline characteristics
Variable
All Patients (n = 1,270)
Age in years, median (range)
63 (13 to 94)
Male, n (%)
1046 (82.4)
Ethnicity
Chinese
1135 (89.4)
Malay
90 (7.1)
Indian
36 (2.8)
Others
9 (0.7)
Aetiology
Hepatitis B
953 (75.0)
Hepatitis C
91 (7.2)
Hepatitis B and C co-infection
48 (3.8)
178 (14.0)
Child-Pugh class
A:B:C
641 (50.5): 452 (35.6): 177 (13.9)